Targeting NAD + Synthesis to Potentiate CD38-Based Immunotherapy of Multiple Myeloma

Antibodies targeting CD38, a NAD -degrading enzyme, have emerged as a promising immunotherapy against multiple myeloma (MM). Currently, the mechanisms by which anti-CD38 antibodies establish their therapeutic effects are poorly understood. Here, we advocate for the depletion of NAD to enhance the ef...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Trends in Cancer 2020-01, Vol.6 (1), p.9-12
Hauptverfasser:	Kennedy, Barry E, Sadek, Maryanne, Elnenaei, Manal O, Reiman, Anthony, Gujar, Shashi A
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	12
container_issue	1
container_start_page	9
container_title	Trends in Cancer
container_volume	6
creator	Kennedy, Barry E Sadek, Maryanne Elnenaei, Manal O Reiman, Anthony Gujar, Shashi A
description	Antibodies targeting CD38, a NAD -degrading enzyme, have emerged as a promising immunotherapy against multiple myeloma (MM). Currently, the mechanisms by which anti-CD38 antibodies establish their therapeutic effects are poorly understood. Here, we advocate for the depletion of NAD to enhance the efficacy of anti-CD38-based immunotherapies in MM.
doi_str_mv	10.1016/j.trecan.2019.11.005
format	Article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2341606227</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2341606227</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-d1f1e737a9d81459cf30aa4cb28db6c3b566b096ce76c8ce547faf5c00cda8a03</originalsourceid><addsrcrecordid>eNo9kF1PwjAUhhujEYL8A2N6aWI2T9u12y4R_CABNRGvm647w5F94Npd8O-FgFyd9-J535M8hNwyCBkw9bgJfYfWNCEHloaMhQDyggx5BDJIgMvLcxZiQMbObQCAScUVj67JQLBU8jiJhmS1Mt0afdms6ftkRh_o167xP-hKR31LP1uPjS-NRzqdiSR4Mg5zOq_rvmn3VGe2O9oWdNlXvtxWSJc7rNra3JCrwlQOx6c7It8vz6vpW7D4eJ1PJ4vACsV9kLOCYSxik-YJi2RqCwHGRDbjSZ4pKzKpVAapshgrm1iUUVyYQloAm5vEgBiR--Putmt_e3Re16WzWFWmwbZ3mouIKVCcx3s0OqK2a53rsNDbrqxNt9MM9EGp3uijUn1QqhnTe6X72t3pQ5_VmJ9L_wLFH2Tvc5M</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2341606227</pqid></control><display><type>article</type><title>Targeting NAD + Synthesis to Potentiate CD38-Based Immunotherapy of Multiple Myeloma</title><source>Alma/SFX Local Collection</source><creator>Kennedy, Barry E ; Sadek, Maryanne ; Elnenaei, Manal O ; Reiman, Anthony ; Gujar, Shashi A</creator><creatorcontrib>Kennedy, Barry E ; Sadek, Maryanne ; Elnenaei, Manal O ; Reiman, Anthony ; Gujar, Shashi A</creatorcontrib><description>Antibodies targeting CD38, a NAD -degrading enzyme, have emerged as a promising immunotherapy against multiple myeloma (MM). Currently, the mechanisms by which anti-CD38 antibodies establish their therapeutic effects are poorly understood. Here, we advocate for the depletion of NAD to enhance the efficacy of anti-CD38-based immunotherapies in MM.</description><identifier>ISSN: 2405-8033</identifier><identifier>EISSN: 2405-8025</identifier><identifier>DOI: 10.1016/j.trecan.2019.11.005</identifier><identifier>PMID: 31952784</identifier><language>eng</language><publisher>United States</publisher><ispartof>Trends in Cancer, 2020-01, Vol.6 (1), p.9-12</ispartof><rights>Copyright © 2019. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-d1f1e737a9d81459cf30aa4cb28db6c3b566b096ce76c8ce547faf5c00cda8a03</citedby><cites>FETCH-LOGICAL-c362t-d1f1e737a9d81459cf30aa4cb28db6c3b566b096ce76c8ce547faf5c00cda8a03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31952784$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kennedy, Barry E</creatorcontrib><creatorcontrib>Sadek, Maryanne</creatorcontrib><creatorcontrib>Elnenaei, Manal O</creatorcontrib><creatorcontrib>Reiman, Anthony</creatorcontrib><creatorcontrib>Gujar, Shashi A</creatorcontrib><title>Targeting NAD + Synthesis to Potentiate CD38-Based Immunotherapy of Multiple Myeloma</title><title>Trends in Cancer</title><addtitle>Trends Cancer</addtitle><description>Antibodies targeting CD38, a NAD -degrading enzyme, have emerged as a promising immunotherapy against multiple myeloma (MM). Currently, the mechanisms by which anti-CD38 antibodies establish their therapeutic effects are poorly understood. Here, we advocate for the depletion of NAD to enhance the efficacy of anti-CD38-based immunotherapies in MM.</description><issn>2405-8033</issn><issn>2405-8025</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNo9kF1PwjAUhhujEYL8A2N6aWI2T9u12y4R_CABNRGvm647w5F94Npd8O-FgFyd9-J535M8hNwyCBkw9bgJfYfWNCEHloaMhQDyggx5BDJIgMvLcxZiQMbObQCAScUVj67JQLBU8jiJhmS1Mt0afdms6ftkRh_o167xP-hKR31LP1uPjS-NRzqdiSR4Mg5zOq_rvmn3VGe2O9oWdNlXvtxWSJc7rNra3JCrwlQOx6c7It8vz6vpW7D4eJ1PJ4vACsV9kLOCYSxik-YJi2RqCwHGRDbjSZ4pKzKpVAapshgrm1iUUVyYQloAm5vEgBiR--Putmt_e3Re16WzWFWmwbZ3mouIKVCcx3s0OqK2a53rsNDbrqxNt9MM9EGp3uijUn1QqhnTe6X72t3pQ5_VmJ9L_wLFH2Tvc5M</recordid><startdate>202001</startdate><enddate>202001</enddate><creator>Kennedy, Barry E</creator><creator>Sadek, Maryanne</creator><creator>Elnenaei, Manal O</creator><creator>Reiman, Anthony</creator><creator>Gujar, Shashi A</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202001</creationdate><title>Targeting NAD + Synthesis to Potentiate CD38-Based Immunotherapy of Multiple Myeloma</title><author>Kennedy, Barry E ; Sadek, Maryanne ; Elnenaei, Manal O ; Reiman, Anthony ; Gujar, Shashi A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-d1f1e737a9d81459cf30aa4cb28db6c3b566b096ce76c8ce547faf5c00cda8a03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kennedy, Barry E</creatorcontrib><creatorcontrib>Sadek, Maryanne</creatorcontrib><creatorcontrib>Elnenaei, Manal O</creatorcontrib><creatorcontrib>Reiman, Anthony</creatorcontrib><creatorcontrib>Gujar, Shashi A</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Trends in Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kennedy, Barry E</au><au>Sadek, Maryanne</au><au>Elnenaei, Manal O</au><au>Reiman, Anthony</au><au>Gujar, Shashi A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeting NAD + Synthesis to Potentiate CD38-Based Immunotherapy of Multiple Myeloma</atitle><jtitle>Trends in Cancer</jtitle><addtitle>Trends Cancer</addtitle><date>2020-01</date><risdate>2020</risdate><volume>6</volume><issue>1</issue><spage>9</spage><epage>12</epage><pages>9-12</pages><issn>2405-8033</issn><eissn>2405-8025</eissn><abstract>Antibodies targeting CD38, a NAD -degrading enzyme, have emerged as a promising immunotherapy against multiple myeloma (MM). Currently, the mechanisms by which anti-CD38 antibodies establish their therapeutic effects are poorly understood. Here, we advocate for the depletion of NAD to enhance the efficacy of anti-CD38-based immunotherapies in MM.</abstract><cop>United States</cop><pmid>31952784</pmid><doi>10.1016/j.trecan.2019.11.005</doi><tpages>4</tpages></addata></record>
fulltext	fulltext
identifier	ISSN: 2405-8033
ispartof	Trends in Cancer, 2020-01, Vol.6 (1), p.9-12
issn	2405-8033 2405-8025
language	eng
recordid	cdi_proquest_miscellaneous_2341606227
source	Alma/SFX Local Collection
title	Targeting NAD + Synthesis to Potentiate CD38-Based Immunotherapy of Multiple Myeloma
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T08%3A08%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeting%20NAD%20+%20Synthesis%20to%20Potentiate%20CD38-Based%20Immunotherapy%20of%20Multiple%20Myeloma&rft.jtitle=Trends%20in%20Cancer&rft.au=Kennedy,%20Barry%20E&rft.date=2020-01&rft.volume=6&rft.issue=1&rft.spage=9&rft.epage=12&rft.pages=9-12&rft.issn=2405-8033&rft.eissn=2405-8025&rft_id=info:doi/10.1016/j.trecan.2019.11.005&rft_dat=%3Cproquest_cross%3E2341606227%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2341606227&rft_id=info:pmid/31952784&rfr_iscdi=true